Terms: = Kidney tumors AND ERBB2, c-erb B2, 2064, P04626, ENSG00000141736, c-erbB2, HER-2/neu, HER2, TKR1, NEU, NGL, HER-2 AND Treatment
104 results:
1. The Predictive Role of Serum Lipid Levels, p53 and ki-67, According to Molecular Subtypes in Breast Cancer: A Randomized Clinical Study.
Faur IF; Dobrescu A; Clim IA; Pasca P; Prodan-Barbulescu C; Tarta C; Neamtu AA; Brebu D; Neamtu C; Rosu M; Duta C; Clim A; Lazar G; Totolici B
Int J Mol Sci; 2024 Mar; 25(7):. PubMed ID: 38612725
[TBL] [Abstract] [Full Text] [Related]
2. [Cytopathological characteristics of SMARCA4-deficient thoracic undifferentiated tumors in serous effusion].
Wang WN; Liu XT; Liang YM
Zhonghua Bing Li Xue Za Zhi; 2024 Feb; 53(2):143-148. PubMed ID: 38281781
[No Abstract] [Full Text] [Related]
3. First-in-Human Evaluation of Site-Specifically Labeled
Yeh R; O'Donoghue JA; Jayaprakasam VS; Mauguen A; Min R; Park S; Brockway JP; Bromberg JF; Zhi WI; Robson ME; Sanford R; Modi S; Agnew BJ; Lyashchenko SK; Lewis JS; Ulaner GA; Zeglis BM
J Nucl Med; 2024 Mar; 65(3):386-393. PubMed ID: 38272704
[TBL] [Abstract] [Full Text] [Related]
4. Hsa_circ_0086414/transducer of erbb2 (TOB2) axis-driven lipid elimination and tumor suppression in clear cell renal cell cancer via perilipin 3.
Meng X; Li W; Yu T; Lu F; Wang C; Yuan H; Yang W; Dong W; Xiao W; Zhang X
Int J Biol Macromol; 2024 Mar; 261(Pt 1):129636. PubMed ID: 38272402
[TBL] [Abstract] [Full Text] [Related]
5. The influence of chronic renal insufficiency on multi-therapeutic modalities for breast cancer: a single-center experience.
Hong YW; Kuo IM; Kuo WL; Yu CC; Shen SC; Tsai HP; Chu CH; Ho HY; Lo YF; Chen SC; Lin YC; Chien CY; Chou HH
Breast Cancer; 2024 Mar; 31(2):252-262. PubMed ID: 38150135
[TBL] [Abstract] [Full Text] [Related]
6. The Role of Transcription Factors in the Loss of Inter-Chromosomal Co-Expression for Breast Cancer Subtypes.
Trujillo-Ortíz R; Espinal-Enríquez J; Hernández-Lemus E
Int J Mol Sci; 2023 Dec; 24(24):. PubMed ID: 38139393
[TBL] [Abstract] [Full Text] [Related]
7. Projected impact of population aging on non-communicable disease burden and costs in the Kingdom of Saudi Arabia, 2020-2030.
Boettiger DC; Lin TK; Almansour M; Hamza MM; Alsukait R; Herbst CH; Altheyab N; Afghani A; Kattan F
BMC Health Serv Res; 2023 Dec; 23(1):1381. PubMed ID: 38066590
[TBL] [Abstract] [Full Text] [Related]
8. Advanced renal pelvis carcinoma patient with an erbb2 insertion mutation: a case report.
Shang P; Lou C; Yin L; Tao C; Dong Y; Yang G; Yuan Z
J Int Med Res; 2023 Nov; 51(11):3000605231204502. PubMed ID: 37917812
[TBL] [Abstract] [Full Text] [Related]
9. treatments During Pregnancy Targeting erbb2 and Outcomes of Pregnant Individuals and Newborns.
Gougis P; Grandal B; Jochum F; Bihan K; Coussy F; Barraud S; Asselain B; Dumas E; Sebbag C; Hotton J; Spaggiari E; Pierga JY; Savarino R; Laas E; Spano JP; Reyal F; Hamy AS
JAMA Netw Open; 2023 Oct; 6(10):e2339934. PubMed ID: 37883083
[TBL] [Abstract] [Full Text] [Related]
10. First-line regorafenib with nivolumab and chemotherapy in advanced oesophageal, gastric, or gastro-oesophageal junction cancer in the USA: a single-arm, single-centre, phase 2 trial.
Cytryn SL; Moy RH; Cowzer D; Shah RH; Chou JF; Joshi SS; Ku GY; Maron SB; Desai A; Yang J; Sugarman R; Rao D; Goldberg Z; Charalambous C; Lapshina M; Antoine A; Socolow F; Trivedi N; Capanu M; Gerdes H; Schattner MA; Simmons M; Lacouture ME; Paroder V; Tang LH; Shia J; Ilson DH; Solit DB; Berger MF; Janjigian YY
Lancet Oncol; 2023 Oct; 24(10):1073-1082. PubMed ID: 37666264
[TBL] [Abstract] [Full Text] [Related]
11. Cost-effectiveness of Trastuzumab Deruxtecan for her2-low Advanced Breast Cancer in the United States.
Peng Y; Wang L; Peng L; Liu Q; Yi L; Luo X; Li S; Qin S; Wan X; Tan C; Chen G
Clin Ther; 2023 Oct; 45(10):965-972. PubMed ID: 37537015
[TBL] [Abstract] [Full Text] [Related]
12. Gene mutation profiling and clinical significances in patients with renal cell carcinoma.
Wang Y; He P; Zhou X; Wang C; Fu J; Zhang D; Liao D; Zhou Z; Wu C; Gong W
Clinics (Sao Paulo); 2023; 78():100259. PubMed ID: 37515929
[TBL] [Abstract] [Full Text] [Related]
13. Efficacy of her2-Targeted Intraperitoneal
Chung SK; Vargas DB; Chandler CS; Katugampola S; Veach DR; McDevitt MR; Seo SH; Vaughn BA; Rinne SS; Punzalan B; Patel M; Xu H; Guo HF; Zanzonico PB; Monette S; Yang G; Ouerfelli O; Nash GM; Cercek A; Fung EK; Howell RW; Larson SM; Cheal SM; Cheung NV
J Nucl Med; 2023 Sep; 64(9):1439-1445. PubMed ID: 37348919
[TBL] [Abstract] [Full Text] [Related]
14. Tucatinib plus trastuzumab for chemotherapy-refractory, her2-positive, RAS wild-type unresectable or metastatic colorectal cancer (MOUNTAINEER): a multicentre, open-label, phase 2 study.
Strickler JH; Cercek A; Siena S; André T; Ng K; Van Cutsem E; Wu C; Paulson AS; Hubbard JM; Coveler AL; Fountzilas C; Kardosh A; Kasi PM; Lenz HJ; Ciombor KK; Elez E; Bajor DL; Cremolini C; Sanchez F; Stecher M; Feng W; Bekaii-Saab TS;
Lancet Oncol; 2023 May; 24(5):496-508. PubMed ID: 37142372
[TBL] [Abstract] [Full Text] [Related]
15. [Unresectable Advanced her2-Positive Gastric Cancer Leading to a Perforation during Chemotherapy with Trastuzumab plus Paclitaxel].
Ogawa T; Watanabe M; Doita S; Minagi H; Miyake E; Hatono M; Kimura Y; Taniguchi F; Arata T; Katsuda K; Tanakaya K; Aoki H
Gan To Kagaku Ryoho; 2022 Dec; 49(13):1452-1454. PubMed ID: 36733099
[TBL] [Abstract] [Full Text] [Related]
16.
Altunay B; Goedicke A; Winz OH; Hertel F; von Mallek D; Meszaros LK; Chand G; Biersack HJ; Stickeler E; Krauss K; Mottaghy FM
Eur J Nucl Med Mol Imaging; 2023 Mar; 50(4):1005-1013. PubMed ID: 36482076
[TBL] [Abstract] [Full Text] [Related]
17. Site-Specific Radiohalogenation of a her2-Targeted Single-Domain Antibody Fragment Using a Novel Residualizing Prosthetic Agent.
Feng Y; Sarrett SM; Meshaw RL; Vaidyanathan G; Cornejo MA; Zeglis BM; Zalutsky MR
J Med Chem; 2022 Nov; 65(22):15358-15373. PubMed ID: 36368007
[TBL] [Abstract] [Full Text] [Related]
18. Identifying Prognostic Biomarkers Related to m6A Modification and Immune Infiltration in Renal Cell Carcinoma.
Ye J; Li P; Zhang H; Wu Q; Yang D
Genes (Basel); 2022 Nov; 13(11):. PubMed ID: 36360294
[TBL] [Abstract] [Full Text] [Related]
19. Real-world data for the renal safety of abemaciclib combined with bisphosphonate in HR+/her2- advanced breast cancer.
Hao C; Bai X; Zhang J; Meng W; Tong Z
Thorac Cancer; 2023 Jan; 14(1):68-72. PubMed ID: 36351632
[TBL] [Abstract] [Full Text] [Related]
20. miR-378a-3p promotes renal cell carcinoma proliferation, migration, and invasion by targeting TOB2.
Bao N; Zhang P; Zhu Y; Du P; Jin G; Wu B; Ding T
Clin Transl Oncol; 2023 Mar; 25(3):748-757. PubMed ID: 36309620
[TBL] [Abstract] [Full Text] [Related]
[Next]
